We are laser-focused on our mission: to improve the lives of patients and their families.

Clinical Trials

Our pipeline programs target kidney diseases of high unmet need, including ADPKD.

Programs

We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics.

Technology

News.

September 12, 2022

Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

September 2, 2022

Regulus Therapeutics to Participate in Upcoming Investor Conferences

August 11, 2022

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

MORE NEWS